Alcohol abstinence was achieved by nearly two thirds of patients with alcohol use disorder (AUD) and cirrhosis after taking naltrexone, with minimal adverse events.
Naltrexone was effective in achieving abstinence, reducing lapses and improving craving scores at 3 months in patients with alcohol-related cirrhosis, according to data presented at EASL Congress.
“In the largest randomized controlled trial available to date, which is a combined trial with 1,380 patients with alcohol use disorder, naltrexone has been shown to have an increased incidence of